Bionomics Limited

Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

Latest Media Releases

Latest News

Company News / by Rachael Jones - 10 months ago

Bionomics to host PTSD meetings

6 Apr 2018 -Global biopharmaceutical company Bionomics (ASX:BNO) today announced they will host Key Opinion Leader meetings focused on the treatment of post traumatic stress disord…